PATIENT-CENTRIC IN ALL WE DO
Biohaven is a modern, tech-savvy company that is agile and inventive, and ready to execute our patient-first commitment with innovative ideas and steadfast focus.
CHALLENGING THE STATUS QUO
At Biohaven, we are guided by science and inspired to change the lives of people with unmet medical needs. Harnessing our non-hierarchical, entrepreneurial structure, we are focused on disrupting the status quo for historically difficult-to-treat diseases, including rare disorders.
We have made rapid progress with multiple compounds across our innovative therapeutic portfolio of programs, spanning late-to-early-stage clinical development.
Multiple clinical trials are ongoing for product candidates across diseases such as obsessive-compulsive disorder (OCD), epilepsy and spinal muscular atrophy (SMA).
FOLLOWING SCIENCE ON BEHALF OF PATIENTS
Biohaven is dedicated to following science, continuously striving to evolve our approach to drug discovery and development to help people live healthier lives. To enhance our ability to deliver enduring value, we have combined internal research and development with intellectual property licensed from companies and institutions including Pfizer, Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital.
Katy M.
Senior Research Scientist
WINNING WITH SCIENCE
Biohaven is dedicated to following science, continuously striving to evolve our approach to drug discovery and development to help people live healthier lives. To enhance our ability to deliver enduring value, we have combined internal research and development with intellectual property licensed from companies and institutions including Pfizer, Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital.
Katy M.
Senior Research Scientist
PROVEN DRUG DEVELOPMENT CAPABILITIES
Biohaven is developing drug candidates based on our five proprietary platforms, all of which are modular in design to enable rapid generation of novel therapies for the treatment of diseases with high unmet medical needs.
Our ability to optimize success across our numerous drug development programs is driven by our proven expertise in clinic execution, where we have demonstrated the ability to operate with unmatched speed and efficiency.
We are advancing an extensive portfolio of late- and early-stage programs across 20 therapeutic indications in neuroscience, immunology and oncology.
DEMONSTRATING THE POWER OF DIGITAL TRANSFORMATION
As a modern pharmaceutical company, Biohaven also has established an agile operating model with a culture of innovation that extends across the R&D lifecycle to all aspects of business. We pride ourselves on being a tech-savvy company and a leader in the use of digital tools and technologies to increase engagement and enhance the success of our novel treatments.
REALIZING OUR MISSION
We believe our future is bright. We intend to realize our mission by delivering a paradigm shift by creating opportunities for breakthrough science with our early-stage R&D engine, executing diligently on our commercial launches, harnessing our digital technology leadership, and building our global partnerships.
We’re just getting started.